# CIPAC STATUS REPORT

**06/12/2009**



## 0683 Clodinafop

Allocated to CH

CIPAC methods published in :

CIPAC M, 26

**CIPAC** 50th meeting, June 2006 in Geneva

Ms. de Benedictis presented the results of a full collaborative study by Syngenta for the determination of clodinafop-propargyl in technical material, and in WP and EC formulations. The sum of both enantiomers was determined using reversed phase HPLC, and UV-detection at 305 nm and external standardisation. The second method determines the enantiomeric purity. Clodinafop-propargyl is separated from the *S*-enantiomer and the enantiomeric ratio is determined by chiral phase HPLC using UV detection at 230 nm. Ten laboratories participated in the study. No outliers or strugglers were identified. Evaluation of RSD according to the Horwitz criteria showed that repeatability is within the accepted range. It was proposed that the determination of clodinafop-propargyl as the pure *R*-enantiomer (achiral and chiral part) be accepted as a provisional CIPAC method.
Decision The non-enantioselective reversed phase HPLC method (CIPAC/4499) for the determination of clodinafop-propargyl in TC, EC and WP formulations was accepted as **provisional** CIPAC method. The enantioselective reversed phase HPLC method for the determination of the *R*-enantiomer was accepted as a quantitative identity test.

**CIPAC** 51th meeting, June 2007 in Umhlanga Rocks, South Africa

Decision The non-enantioselective reversed phase HPLC method (CIPAC/4499) for the determination of clodinafop-propargyl in TC, EC and WP formulations was accepted as **full** CIPAC method.